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Abstract: The cytokine transforming growth factor-β (TGF-β) plays an important role in the maintenance of T cell homeostasis, immune
tolerance to self-antigens, and T cell differentiation during immune responses. TGF-β has pleiotropic effects on adaptive immune
responses, especially on the differentiation of T helper and T regulatory cell populations, which depends on the T cell differentiation
status and the stimulation conditions. This review provides an update about the roles of TGF-β in T cell responses, especially in the
regulation of Treg development and biological features under steady state and inflammation. We also discuss the additional roles that
TGF-β plays in the development and function of other T helper cells, such as Th1, Th2, Th9, Th17, and Th22 cells during inflammation.
Key words: Transforming growth factor-β, T helper cells, T regulatory cells

1. Introduction
Transforming growth factor-β (TGF-β) is a highly
evolutionarily conserved cytokine consisting of three
known mammalian family members (TGF-β1, -β2,
and -β3) that regulate multiple physiological processes.
TGF-β1 is produced by many types of immune cells
and nonimmune cells. T cells, T regulatory (Treg) cells,
macrophages, effector T cells, and thymic mesenchymal
cells and tumor cells are the main sources of TGF-β1
production. As TGF-β1 mainly regulates immune
responses and the current review focuses on the immune
system, we have used TGF-β to replace TGF-β1 in the
review.
TGF-β1 is the predominant isoform expressed in the
immune system, and its widespread regulatory activity
affects multiple types of immune cells (Li et al., 2006b).
Mice that lack this isoform either die embryonically or,
if surviving, develop multiorgan inflammation and die
at an early age (Shull et al., 1992). This phenomenon has
highlighted a crucial role for TGF-β in dampening selfharmful inflammatory responses. Nevertheless, TGF-β is
more than an immunosuppressive cytokine. For instance,
early studies also revealed that TGF-β induces stimulatory
or inhibitory effects in human T cells, which depends
on the T cell differentiation status and the stimulation
conditions (de Jong et al., 1994). This context-dependent
* Correspondence: szheng1@hmc.psu.edu

function of TGF-β allows for its distinctive roles in T cell
development, homeostasis, tolerance, and differentiation.
TGF-β is synthesized in a latent form that has to be
activated via binding to the TGF-β receptor complex.
Binding of active TGF-β to its receptor complex triggers
receptor serine/threonine kinase activity, allowing for
recruitment of the intracellular receptors Smad2 and
Smad3 to the cytoplasmic domain of activated TGFβRI, which directly phosphorylates Smad2/3. Hereafter,
Smad2/3 forms a trimeric structure with Smad4, which
translocates to the nucleus to activate or repress gene
expression via binding to Smad-responsive regulatory
regions. Indeed, recent evidence has suggested that,
during differentiation of Th17 cells, different isoforms of
TGF-β may activate different Smad signaling pathways
(Lee et al., 2012). Hence, it appears that alternative
Smad signaling pathways may be initiated by TGF-β
in a context-dependent way, although further work
is required to determine the biological relevance
of differential Smad activation in the regulation of
immunity.
In addition, TGF-β can also trigger numerous Smadindependent signaling pathways. For example, signaling
via MAP kinases, PI3 kinase, and Rho GTPases all can
be triggered by TGF-β receptor engagement (Mu et al.,
2012). Further studies are needed in the field of how
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and when Smad-dependent and -independent signaling
pathways are triggered by TGF-β in immune cells and the
relative pleiotropic effects of TGF-β on immune responses.
2. Function of TGF-β in the development of Treg cells
TGF-β contributes to suppression of T cell-mediated
immune responses through either direct or indirect
pathway. It is undoubted that TGF-β directly suppresses
T cell responses since T cells express TGF-β receptors. A
milestone discovery has revealed that TGF-β can induce T
suppressor or regulatory cells (Zheng et al., 2002), and then
indirectly clamp down T cells responses (Zheng et al., 2004a,
2004b). Treg cells are a subset of T cells that are crucial in
maintaining homeostasis via suppression of self-harmful T
cell responses (Josefowicz et al., 2012a). The transcription
factor Forkhead box P3, abbreviated as Foxp3, is a specific
marker of Treg cells, and its expression is a typical requisite
for Treg cell differentiation and function (Hori et al., 2003).
Mice with a mutation in Foxp3 (Brunkow et al., 2001) or
with a targeted knockout of Foxp3 in T cells (Fontenot
et al., 2005) die of multiorgan inflammation very early in
life, akin to mice lacking TGF-β1. Also, humans carrying
an inactivating mutation in the FOXP3 gene develop
immunodysregulation, endocrinopathy, and enteropathy
X-linked (IPEX) syndrome, a severe autoimmune disease
generally resulting in death around 2 years of age (van der
Vliet and Nieuwenhuis, 2007). There are two major subtypes
of Tregs: natural Tregs (nTregs), which are naturally
occurring, thymus-derived CD4+CD25+ Treg cells, and
induced Tregs (iTregs), which are induced with cytokines
TGF-β and IL-2 (Zheng et al., 2002, 2007). Interestingly,
lacking TGF-β does not affect nTreg cell development
and function (Piccirillo et al., 2002), and thus TGF-β
appears to play pivotal but different roles in regulating the
development of nTreg and iTreg subpopulations.
2.1. TGF-β signal and nTreg development
CD4+ and CD8+ T cells can convert to effector T cells
conventionally during inflammation and autoimmune
responses. Conversely, they can also differentiate to
T regulatory cell lineages in the thymus (Kronenberg
and Rudensky, 2005). The development of nTreg cells is
determined by the interaction between TCRs and MHC
II–self peptide, costimulation, and cytokine signaling
pathways (Liston and Rudensky, 2007). Two studies
demonstrated that nTreg numbers were similar (Marie
et al., 2006) or increased (Li et al., 2006a) in TGF-βRII T
cell-specific deletion mouse models compared with control
mice. It is plausible that TGF-β is dispensable to the
development of nTreg cells. However, another study with
the conditional Tgfr1 gene T cell-specific deletion mouse
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models demonstrated that TGF-β deficiency hindered
nTreg cell differentiation in 3- to 5-day-old mice but
touched off nTreg cell expansion in mice 1 week later (Liu
et al., 2008). It needs further study to determine whether
or how TGF-β signaling affects nTreg development and
expansion in different stages of life.
The nTreg cell proliferation in the later stage can be
observed in TGF-βRII-deficient mice (Li et al., 2006b),
and it is postulated that the cytokine interleukin-2 (IL-2)
has boosted nTreg cell expansion with flowing immune
responses to antigens. This is further validated by the
observation that genetic ablation of IL-2 in TGF-βRIdeficient mice reduced the quantity of thymic nTreg cells
(Liu et al., 2008). IL-2 also promotes the development and
maintenance of iTreg cells (Davidson et al., 2007; Zheng
et al., 2007). Subsequent work has showed that TGF-β
signaling in T cells protects nTregs from apoptosis during
thymic development by suppression of proapoptotic
proteins and upregulation of the antiapoptotic protein Bcl2 (Ouyang et al., 2010).
Central T cell tolerance consists of diversified
mechanisms, of which two main mechanisms are to induce
high-affinity self-reactive T cells apoptosis in the thymus
(Mathis and Benoist, 2004) and to keep monitoring
escaped autoreactive T cells (Walker and Abbas, 2002). In
contrast, peripheral T cell tolerance is mainly controlled by
CD4+Foxp3+ Treg cells, in which TGF-β1 plays a critical
role in suppressing T-mediated autoimmunity and Treg
cell development (Li et al., 2006b; Sakaguchi et al., 2008).
Mice suffer from fatal autoimmune diseases if lacking
either TGF-β1 or Foxp3, the latter being the transcription
factor needed for Treg cell development and function.
2.2. TGF-β signal and iTreg development
In addition to nTreg cell development in the thymus, iTreg
cells can be differentiated from naive T cells and acquire
the function of Foxp3 expression in peripheral tissues
in vitro and in vivo (Zheng et al., 2002; Bluestone and
Abbas, 2003). It has been suggested that TGF-β-induced
Foxp3 expression was mediated by the recruitment of
its downstream transcription factor Smad2/3 to a Foxp3
enhancer element by distinct mechanisms. In the setting
of TCR engagement, Smad3 interacts with an enhancer
region of the Foxp3 gene called CNS1 (Tone et al.,
2008; Zheng et al., 2010). Smad3 also modulates Foxp3
expression by forming an enhanceosome complex along
with NFATc2 and CREB at the Foxp3 promoter (Xu et al.,
2010a). Furthermore, TGF-β-induced expression of Foxp3
is partially reduced in Smad3 knockout T cells (Martinez
et al., 2009). Smad2 does not bind directly to the CNS1
region, but it does play a role in the TGF-β-mediated iTreg
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induction, given that T cells lacking Smad2 have a reduced
ability to upregulate Foxp3 expression (Lu et al., 2010a).
Loss of both Smad2 and Smad3 resulted in complete
ablation of Foxp3 upregulation by TGF-β (Takimoto et
al., 2010), supporting a cooperative interaction between
Smad2 and Smad3 in the induction of iTregs. In addition
to Smad-mediated effects, TGF-β can indirectly promote
Foxp3 induction by inhibiting factors that normally
suppress Foxp3, such as the transcriptional repressor Gfi1 (Zhu et al., 2009). Otherwise, the cytokine IL-2 that
derives from T cells enhances iTreg cell differentiation
induced by TGF-β (Zheng et al., 2007, 2004a), which
triggers the transcription factor STAT5, and STAT5 may
synergize with Smad3 for binding to the Foxp3 promoter
(Burchill et al., 2007).
Some experiments have demonstrated that when
TGF-β is expressed in the microenvironment excessively, it
can evoke Foxp3 expression and iTreg cell differentiation.
For instance, overexpression of TGF-β1 in the pancreatic
islets in nonobese diabetic mice leads to the proliferation of
CD4+Foxp3+ Treg cells that prevents mice from suffering
from diabetes mellitus (Peng et al., 2004). The induction of
iTreg cells in the peripheral microenvironment also may
require endogenous TGF-β. Low doses of TGF-β can also
induce naive T cells to differentiate to iTreg cells through
stimulating steady-state dendritic cells in peripheral
tissues de novo (Kretschmer et al., 2005). The courses of
this differentiation seemed to be attenuated by effector T
cell expansion, costimulation with CD40 antibody agonist,
or excessive extrinsic antigens. However, these polarized
iTreg cells exhibit a stable phenotype and could expand
in inflammation status. In DNRII-expressing mice,
when the TGF-β signaling is blocked in naive T cells, the
differentiation of iTreg cells is significantly reduced, and T
cells manifest the enhanced expansion conversely.
Foxp3 instability in the inflammatory conditions not
only affects the Treg phenotype but also compromises
its function. nTreg can convert into Th1, Th2, Th17, and
T follicular helper (Tfh) cells in the presence of IL-6 or
TNF-α (Wan and Flavell, 2007; Xu et al., 2007; Zheng et
al., 2008a; Tsuji et al., 2009; Lu et al., 2010a). iTreg stability
is still controversial. Some studies suggest that iTregs are
unstable (Koenecke et al., 2009), and the Treg-specific
demethylated region (TSDR) in iTregs has incomplete
demethylation that possibly contributes to their instability
(Floess et al., 2007). Nonetheless, recent studies have also
demonstrated that iTregs are stable and functional if the
appropriate protocol to generate iTregs is used (Gu et al.,
2014). iTregs are completely resistant to Th17 conversion
while nTregs are not (Zheng et al., 2008a; O’Connor et al.,

2012). In the EAE model, iTregs are sufficiently functional
and even began to express the Th1 cytokine (O’Connor
et al., 2012). In the CIA model, iTregs have demonstrated
superior stability and functionality to nTregs (Kong et al.,
2012). Furthermore, iTreg cells induced in vivo appear to
express Foxp3 stably and display a demethylated TSDR
region (Polansky et al., 2008). Thus, further studies
are required to investigate the mechanisms regulating
the stability of Foxp3 induction by TGF-β in different
immunological contexts.
Naive T cells in transgenic mouse models could also
convert to iTreg cells when the mice were administered
antigens orally (Coombes et al., 2007). The vitamin A
metabolite retinoic acid (atRA) has been attributed to
this prior conversion of iTregs at the mucosal site. TGFβ-mediated induction of Foxp3 is enhanced by atRA
(Benson et al., 2007), which can be secreted by GALT
DCs and macrophages to promote iTreg induction in the
intestine (Coombes et al., 2007; Sun et al., 2007), lungs
(Soroosh et al., 2013), and skin (Guilliams et al., 2010).
atRA facilitates iTreg induction by binding to regulatory
elements in the Foxp3 promoter and enhancer regions,
and by enhancing TGF-β-mediated histone acetylation
at the Foxp3 promoter, then promoting phosphorylated
Smad3 binding to the CNS1 enhancer region of the Foxp3
gene (Kang et al., 2007; Xu et al., 2010b; Lu et al., 2011),
or indirectly by inhibiting proinflammatory cytokine
production by effector/memory T cells and dampening
the responsiveness of T cells to proinflammatory cytokines
(which normally block iTreg induction) (Hill et al., 2008;
Takaki et al., 2008). atRA also promotes the development
of human iTregs and stabilizes nTreg cells in inflammatory
conditions (Lu et al., 2010b, 2014; Zhou et al., 2010).
It is worth noting that when administering neutralizing
TGF-β antibody or atRA receptor inhibitors, iTreg cell
generation was inhibited dramatically. Nevertheless, the
delivery of atRA enhanced the function of TGF-β in the
preferential induction of iTreg cells (Benson et al., 2007;
Coombes et al., 2007; Sun et al., 2007). Accordingly,
mucosal antigens derived from commensal flora or dietary
sources without adverse effects may mainly contribute to
induced peripheral immune tolerance.
2.3. Roles of TGF-β in Treg maintenance and function
Mice lacking TGF-β1 (Marie et al., 2005) or TGF-βRII on T
cells (Li et al., 2006a) display marked reductions in Foxp3+
Treg numbers in the periphery, suggesting a role for TGF-β
in the maintenance of Treg cells. However, repopulation
of mice lacking TGF-βRII on T cells with wild-type Tregs
did not prevent multiorgan inflammation (Li et al., 2006a;
Marie et al., 2006). One explanation for these results is
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that Foxp3+ Treg-mediated suppression of effector T
cells requires TGF-β responsiveness in those cells, which
has been confirmed in mice models of colitis (Fahlen et
al., 2005). In some studies, peripheral Treg numbers are
diminished in the absence of TGF-β production/signaling.
However, using a mouse model lacking the CNS1 enhancer
of the Foxp3 gene that is required for TGF-β-mediated
upregulation of Foxp3 expression and iTreg induction
(Josefowicz et al., 2012b), a study revealed that these
mice did not develop the severe, early-onset multiorgan
inflammation seen in mice lacking all Tregs, suggesting
that nTregs are sufficient to prevent this phenotype. This
conclusion is not consistent with the observation that,
in older mice lacking iTregs, Th2-mediated pathology
developed in the lungs and intestine, with altered bacterial
species detected in the gut (Josefowicz et al., 2012b),
indicating that iTregs are important in controlling immune
responses in some peripheral tissues. Thus, further work
is required to definitively determine the contributions of
iTregs and nTregs at mucosal surfaces and other tissues.
Although many different cell types produce TGF-β, the
discovery that mice with T cell-specific Tgfb1 deficiency
develop autoimmunity and exhibit early mortality around
6 months of age (Li et al., 2007) highlights the importance
of T cell-derived TGF-β in the regulation of T cell tolerance.
It was further demonstrated that iTreg cells are a main
source of active TGF-β that contributes to producing the
next generation of iTregs through a phenomenon called
“infectious tolerance” and long-term immune tolerance
(Horwitz et al., 2004; Zheng et al., 2004a).
Recent work has suggested that an additional
CD4+Foxp3– Treg population also has an important
suppressive function and that this subset is characterized
by cell surface expression of the latency-associated peptide
(LAP) (da Cunha and Weiner, 2012). It is known that TGF-β
needs to interact with LAP and then is released into the active
form. Investigators call these cells Th3-type Tregs and they
are important for the suppressive effects mediated by antiCD3 antibody in several autoimmune diseases (da Cunha
and Weiner, 2012). TGF-β has also been shown to induce
expression of CD73 on activated T cells independently of
Foxp3 expression, which can induce adenosine to suppress
T cell proliferation (Regateiro et al., 2011). Additionally,
by costimulation with IL-27, TGF-β can drive induction
of Tr1 cells, which are a Foxp3– suppressive CD4+ T cell
subpopulation characterized by high expression of IL-10
(Awasthi et al., 2007; Maynard et al., 2007). It is unclear why
Foxp3 expression does not occur in this condition and the
potential role of TGF-β in regulating Foxp3– Treg subsets
deserves further exploration.
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3. Function of TGF-β in T helper cell differentiation
It has been recognized that TGF-β blocks the production
of IL-2 and the expression of IL-2 receptor that inhibits the
development and expansion of T helper cells (Letterio and
Roberts, 1998), and TGF-β provides costimulatory function
for T cells instead when the level of IL-2 is sufficient
to antagonize these blocking effects (Lan et al., 2012).
Nonetheless, TGF-β inhibits naive CD4+ T cells’ conversion
to Th1 or Th2 cells but promotes naive CD4+ and CD8+
cells to differentiate to Treg cell lineages (Ludviksson et al.,
2000; Zheng et al., 2004b; Ma et al., 2014). Thus, TGF-β, as
a pleiotropic cytokine, plays a vital role in effector response
and tolerance in a context-dependent mechanism. TGF-β
can also induce activated CD4+ and CD8+ cells to become
various other T cell subsets, such as Th1, Th2, and Th9,
as well as Th17 cells under certain conditions, which is
explained below in detail.
3.1. Th1 and Th2 cell differentiation
TGF-β can broadly impede T cell activation by inhibiting
TCR signaling, but it also inhibits specific T helper subsets
by suppressing lineage-defining transcription factors,
such as T-bet and GATA-3, which are critical for Th1 and
Th2 cell differentiation, respectively (Gorelik et al., 2000;
Neurath et al., 2002). Indeed, TGF-β signaling-deficient
CD4+ T cells produce increased Th1 and Th2 cytokines
(Gorelik and Flavell, 2000). Recent work has elucidated
the nonredundant roles of the transcription factors Smad2
and Smad3 in TGF-β inhibition of Th1 cell differentiation
(Takimoto et al., 2010; Gu et al., 2012). The Smad signaling
pathway also mediates TGF-β inhibition of Th2 cell
differentiation by inducing the transcription factor Sox4,
which interferes with GATA-3 activity (Kuwahara et al.,
2012).
3.2. Th17 cell differentiation
A role for TGF-β in the induction of the Th17 lineage
was established through in vitro differentiation assays
and in vivo observations that mice with defective TGF-β
signaling possessed fewer IL-17-producing T cells, whereas
overexpression of Tgfb1 led to an increase in Th17 cells
(Bettelli et al., 2006; Mangan et al., 2006; Veldhoen et al.,
2006). Mechanistically, TGF-β is suggested to promote
the Th17 lineage by inhibiting the differentiation of
other helper subsets, as stimulation with IL-6 alone was
sufficient to induce IL-17 production in CD4+ T cells
lacking essential Th1 and Th2 molecules (Das et al., 2009).
Accordingly, TGF-β enhances IL-17 production in CD4+
T cells by suppressing mediated suppression of Gfi-1 and
eomesodermin, which promotes Th2- and Th1-associated
cytokines, respectively (Zhu et al., 2009; Ichiyama et al.,
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2011). Other environmental factors, such as IL-2, atRA, and
IL-6, also influence the development of a specific lineage.
For example, IL-2 and atRA promote iTregs but restrain
Th17 cells, while IL-6 has an opposite role that promotes
Th17 but inhibits iTreg cell development (Bettelli et al.,
2006; Davidson et al., 2007; Laurence et al., 2007; Zheng et
al., 2007; Lu et al., 2011). At the molecular level, it has been
shown that TGF-β can induce the same CD4+ T cells to
express both Foxp3 and RORγt (the key Th17 transcription
factor). As Foxp3 inhibits RORγt activity, TGF-β can favor
iTreg cell development (Zhou et al., 2008). However, TGF-β
was shown to be dispensable for murine Th17 differentiation,
as stimulation with IL-23, IL-6, and IL-1β was also sufficient
to induce IL-17 production by CD4+ T cells (Romagnani et
al., 2009; Ghoreschi et al., 2010). These Th17 cells, but not
those IL-17-producing cells cultured with TGF-β and IL-6,
could induce EAE in a transfer model of disease (McGeachy
et al., 2007), because these pathogenic cells may produce
little IL-10 and express high levels of T-bet (Ghoreschi et al.,
2010). Although Treg cells could provide sufficient amounts
of TGF-β1 to induce in vitro Th17 differentiation (Veldhoen
et al., 2006), Treg cell-derived TGF-β1 was not required for
in vivo differentiation (Gutcher et al., 2011). This research
suggests that autocrine TGF-β1 signaling is essential for
in vivo Th17 differentiation. This was confirmed by mixed
bone marrow chimera experiments showing that Tgfb1deficient T cells failed to produce IL-17 even in the presence
of wild-type cells (Gutcher et al., 2011).
3.3. Th9 cell differentiation
Th9 cells are a recently discovered T helper cell lineage,
which predominantly produces IL-9. Th9 cells were
identified as an important regulator in respiratory tract
epithelial pathogenesis and inducing EAE (Elyaman et al.,
2012; Xiao et al., 2012). It was revealed that IL-9 from mast
cells recruits Treg cells to skin grafts to inhibit graft-versushost disease (Lu et al., 2006). Nonetheless, the exact role of
Th9 cells in the immune system has not been defined.
Th9 cells were initially regarded as a derivative of Th2
cells to cease the expression of IL-4 and initiate production
of IL-9 that resulted from the polarization of other
transcription factors such as interferon regulatory factor
4 (IRF4) and purine-rich box 1 (PU.1) (Chang et al., 2005,
2010; Veldhoen et al., 2008; Staudt et al., 2010). However,
other investigations suggest that up to 80% of the naive
CD4+ T cells can be directly induced to differentiate to
Th9 cells in the culture conditions of TGF-β and IL-4
when OX40 is also administrated (Xiao et al., 2012).
TGF-β alone can promote the differentiation of Treg
cells while IL-4 alone can convert to induce Th2 cells.
Interestingly, the combination of TGF-β and IL-4 provides

the optimal cytokine culture for Th9 cell polarization.
Further study demonstrated that Th9 differentiation
is complicated and identified Th9 cells as a distinctive
lineage rather than Th2 and Treg cells. IL-4 triggers STAT6
and IRF4, and TGF-β triggers PU.1 and inhibits GATA3
(GATA-binding protein 3) and T-bet (T-box expressed
in T cells). However, the combination of TGF-β and IL-4
finally induces only IL-9 expression without IL-4 or IL10 (Murphy and Reiner, 2002; Ansel et al., 2006; Perumal
and Kaplan, 2011). Furthermore, the engagement of OX40
under Treg- or Th17-converting conditions appears to
block the expression of Foxp3+ or IL-17. Therefore, the
function of OX40 on Th9 differentiation remains a topic for
further investigation (Xiao et al., 2012). In the conditions
of TGF-β and IL-4, the transcription factors PU.1 and IRF4
have been identified as the crucial promoters in Th9 cell
induction (Chang et al., 2010; Staudt et al., 2010). Under
OX40 costimulation, the cytokine IL-10 could not be
detected in Th9 cells. However, without the combination
of TGF-β and IL-4, OX40 signaling turns to induce Th1
and Th2 differentiation (Xiao et al., 2012).
3.4. Th22 cell differentiation
Th22 cells have been suggested to be a new T helper cell
subset, since they produce IL-22 but not IFN-γ, IL-4, and
IL-17 (Duhen et al., 2009; Trifari et al., 2009). Th22 cells are
mainly distributed to epithelial tissues and keratinocytes,
and they play an important role in skin homeostasis and
inflammation. The transcription factor aryl hydrocarbon
receptor (AHR) is required for the development of Th22
cells (Trifari et al., 2009; Ramirez et al., 2010) and the
administration of AHR increases IL-22 production and
decreases IL-17 expression. Th22 cells express a high level
of AHR. Th22 cells express only low or undetectable levels
of transcription factors RORγt and T-bet, required in the
generation of Th17 and Th1 cells (Duhen et al., 2009). In
addition, Th22 cells also express the chemokine receptor
CCR6, the skin homing receptor CCR4, and CCR10, which
are culprit cytokines for skin and mucosa diseases, such as
infections, autoimmune diseases, and tumors. Thus, it is
likely that Th22 cells are closely associated with skin and
mucosa immune homeostasis and inflammation (Duhen et
al., 2009; Trifari et al., 2009).
Recent studies also demonstrated that the level of
Th22 cells and IL-22 increased in infection sites (Zheng et
al., 2008b), in inflamed intestines of IBD or CD patients
(Andoh et al., 2005; Wolk et al., 2007), and in primary
tumor tissue (Jiang et al., 2011, 2013). Thus, it has been
suggested that IL-22 and Th22 cells may be important for
the pathogenesis of these skin and mucosa diseases.
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Th22 and Th17 cells are identified to be crucial IL22 producers (Duhen et al., 2009; Trifari et al., 2009).
TGF-β promotes Th17 but not Th22 differentiation, and,
conversely, it suppresses Th22 differentiation (Ghoreschi et
al., 2010). Naive CD4+ T cells can differentiate into Th22
cells in the presence of cytokines IL-6 and TNF-α and
this differentiation is further enhanced by the addition of
IL-1β (Duhen et al., 2009). Additionally, another study
showed that Langerhans cells may also regulate Th22 cell
development (Fujita et al., 2009).
Interestingly, activated CD4+ cells still maintain the
function of expressing some levels of IL-22 when cultured in
Th1-, Th2-, Th17-, or Treg-conversion conditions (Eyerich
et al., 2009), although a high dose of TGF-β (5 ng/mL) can
reduce the production of IL-22. Other effector cells such
as CD8+ T cells and NK cells also produce IL-22; however,
the level IL-22 produced is insufficient to exert their
functional activity in immune responses. It still remains
unclear how the regulatory factors and transduction
mechanism are involved in Th22 cell differentiation.
Moreover, the relationships among Th22 cells and other
IL-22-producing cells in local immune responses need to
be further investigated.
4. Roles of miRNAs in TGF-β-dependent T cells’
differentiation and function
miRNAs are short, noncoding RNAs that regulate gene
expression and mainly cause gene silencing via degradation
of target mRNAs and inhibition of translation (Makeyev et
al., 2008). Numerous individual miRNAs were identified as
important regulators in phenotypic stability, differentiation,
and plasticity of T cells inducing Treg cells (Baumjohann
et al., 2013). As a result, miRNAs modify many cellular
signaling pathways and regulate autoimmune disease
processes (Ambros, 2004; Bartel, 2004).
One recent study indicated that the differential
expression of miRNAs may affect naive CD4 T cells’
differentiation into iTregs by reducing TGFβR1 and
SMAD4 and then altering the TGF-β signal pathway in
patients with multiple sclerosis (Severin et al., 2016.). In
addition, the combination of these miRNAs, such as miR141/500/let-7b, exhibited significant synergistic effects on
the decrease of iTreg development (Severin et al., 2016.).
Nevertheless, these miRNAs only limit Treg development,
not IL-10 production and function of iTreg cells.
The correlation between TGF-β and miRNAs also
affects pathogenic cells. For example, the expression of
miR-323-3p in IL-22/IL-17-producing T cells increased
in patients with asthma and atopic dermatitis. Study has
demonstrated that miR-323-3p may suppress STAT3
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mRNA, whereas TGF-β may promote Th22 cells (Kärner
et al., 2016). Upon accumulation of IL-22 and IL-17,
miR-323-3p produced by T cells inhibits the expression
of SMAD2, SMAD3, and STAT3, resulting in diminished
production of IL-22. SMAD2, SMAD3, CDKN1B, and
STAT3 are important transcription factor from the TGF-β
signaling pathway. SMAD2 and SMAD3 have been
demonstrated to inhibit the development of Th17 cells and
are subject to TGF-β receptor-mediated phosphorylation
and subsequent activation (Rubtsov et al., 2007; Lu et al.,
2010a). Thus, targeting some specific miRNAs may have
a potential to regulate the balance between Treg and T
effector cell with clinical benefits.
It has been noted that the targeting of miRNAs as
therapeutic agents has several problems. For instance, these
miRNAs might regulate other genes outside of the TGF-β
signaling pathway and cause severe side effects. However,
since miRNAs are easily quantified from cells, tissue, and
blood, they may at least serve as appropriate biomarkers in
evaluating the onset, development, therapeutic responses,
and progress of many autoimmune diseases.
5. Conclusion
It seems for now that maintaining the balance among Treg
cells and other T helper cells is a dynamically regulated
and context-dependent process that allows the immune
system to appropriately initiate and resolve immune
responses to invading pathogens and tumors, while
preventing autoimmunity and limiting collateral tissue
damage and immunopathology. Treg homeostasis is
governed by a number of factors, ranging from cytokines,
TCR, and costimulatory signaling to APC. Among these
factors, TGF-β is vital to induce Treg development and
function, and also to affect the differentiation of other
T helper subsets through regulation factors including
miRNA (miR-141/500/let-7b/miR-323-3p) and TGF-β
downstream pathways (Smad and non-Smad pathways)
(Figure). These mechanisms will facilitate the finding
of a promising approach for treating chronic infection,
autoimmunity, and cancers. Similarly, these strategies
also help to control the side effects that can arise from
the presence of more or fewer Treg or Th cells. Although
targeting miRNAs or TGF-β downstream pathways as
therapeutic agents may involve many problems including
severe side effects, they at least can serve as biological
biomarkers in many autoimmune diseases. Nonetheless,
further studies are required to determine the ways to
manipulate TGF-β signals for the treatment of relevant
diseases in the clinic.
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Figure. Function of TGF-β in the development of Treg cells and T helper cells. TGF-β induces stimulatory or inhibitory effects in T cells by
triggering numerous Smad-dependent or -independent signaling pathways in a context-dependent way. TGF-β protects nTregs from apoptosis
during development by upregulation of the antiapoptotic protein Bcl-2. TGF-β is essential for iTreg differentiation by the interaction between
Smad2 and Smad3 and the activation of Foxp3 gene expression. Some miRNAs such as miR-141/500/let-7b may affect the naive CD4 T cells’
differentiation into iTregs by reducing TGF-βR1 and SMAD4. TGF-β suppresses transcription factors, T-bet, and cytokine eomesodermin, which
are critical for Th1 cell differentiation. TGF-β also inhibits Th2 cell differentiation by inducing the transcription factor Sox4 and interfering
with GATA-3 activity. The combination of TGF-β and IL-4 when OX40 is also administrated provides the optimal cytokine culture for Th9 cell
polarization. IL-4 triggers STAT6 and IRF4, and TGF-β triggers PU.1 and inhibits GATA3 and T-bet. TGF-β suppresses Th22 differentiation and
the production of IL-22. miR-323-3p inhibits the expression of SMAD2, SMAD3, and STAT3, which results in diminished production of IL-22.
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